Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization

• Published in: Frontiers in immunology Vol. 11; p. 2171
• Main Authors: Sasaki, Eita, Asanuma, Hideki, Momose, Haruka, Furuhata, Keiko, Mizukami, Takuo, Hamaguchi, Isao
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 11.09.2020
• Subjects: adjuvant; Adjuvants, Immunologic - administration & dosage; Adjuvants, Immunologic - pharmacology; Adjuvants, Immunologic - toxicity; Administration, Intranasal; Animals; Antibodies, Viral - biosynthesis; Antibodies, Viral - immunology; biomarker; Biomarkers; Bronchoalveolar Lavage Fluid; Cytotoxicity, Immunologic - drug effects; Dose-Response Relationship, Immunologic; Drug Evaluation, Preclinical; Female; Gene Expression Regulation - drug effects; Gene Expression Regulation - immunology; genomics; Immunization - methods; Immunoglobulin A - biosynthesis; Immunoglobulin A - immunology; Immunoglobulin G - biosynthesis; Immunoglobulin G - blood; Immunology; influenza; Influenza Vaccines - administration & dosage; Influenza Vaccines - immunology; Lung - drug effects; Lung - immunology; Lung - metabolism; Mice; Mice, Inbred BALB C; nasal vaccine; T-Lymphocyte Subsets - immunology; Th1-Th2 Balance - drug effects; Tissue Inhibitor of Metalloproteinase-1 - biosynthesis; Tissue Inhibitor of Metalloproteinase-1 - genetics; type 1 interferon; Vaccines, Inactivated - administration & dosage; Vaccines, Inactivated - immunology; influenza; type 1 interferon; nasal vaccine; genomics; biomarker; adjuvant

The efficacy of vaccine adjuvants depends on their ability to appropriately enhance the immunogenicity of vaccine antigens, which is often insufficient in non-adjuvanted vaccines. Genomic analyses of immune responses elicited by vaccine adjuvants provide information that is critical for the rational...